Adamis Pharmaceuticals (ADMP) Earning Somewhat Favorable News Coverage, Accern Reports
Media stories about Adamis Pharmaceuticals (NASDAQ:ADMP) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Adamis Pharmaceuticals earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 46.3376715694451 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Adamis Gains Footing on Citing Goals, Accomplishments (baystreet.ca)
- Zacks Investment Research Lowers Adamis Pharmaceuticals (ADMP) to Sell (americanbankingnews.com)
- Two Eye-Catching Stocks: Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), Benchmark Electronics Inc. (NYSE … – The Oracle Examiner (oracleexaminer.com)
- Adamis Pharmaceuticals Corporation (ADMP)- Profitability Ratios Analysis – Nasdaq Fortune (press release) (nasdaqfortune.com)
- What is ATR in technical analysis? Adamis Pharmaceuticals Corporation (ADMP) – Wall Street Morning (wallstreetmorning.com)
Several research firms have issued reports on ADMP. Maxim Group set a $5.00 price target on Adamis Pharmaceuticals and gave the company a “buy” rating in a report on Monday. B. Riley set a $10.00 price target on Adamis Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, November 30th. Raymond James Financial set a $7.00 price target on Adamis Pharmaceuticals and gave the company a “buy” rating in a report on Friday, February 23rd. Zacks Investment Research cut Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 20th. Finally, ValuEngine cut Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 30th. Two analysts have rated the stock with a sell rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $7.33.
TRADEMARK VIOLATION NOTICE: This story was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/adamis-pharmaceuticals-admp-earning-somewhat-favorable-news-coverage-accern-reports/1946881.html.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.